Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Oct 25, 2022 10:08am
137 Views
Post# 35046345

RE:New tech for skin care

RE:New tech for skin careEveryone has a product to improve beauty/skin etc

It all boils down to hard objective results with clinical backing. The results, if impressed will drive the enterprise value as the compound is Novel, meaning there is nothing like it on the market. It is 100% Sirona invention.

On that front I think the value of anti-aging will be correlated to the effectiveness to impact/rebuild the subdermal and dermal layers. Photos would be helpful for the average investor to see.

The question is whether the R&D clinical results will be owned and controlled by Sirona and not the other party participating in the clinical. If its owned by them, they then have the full privelege of shopping the deal widely.

If the results are in fact very impressive then that would mean tremendous upside from 11 cents.
<< Previous
Bullboard Posts
Next >>